A worldwide increase in cancer prevalence has led to advances in diagnostic techniques. According to GLOBOCAN 2020, the estimated prevalence of cancer worldwide is 19,292,789 cases, of which the estimated prevalence of breast cancer is 2,261,419 cases. The rising geriatric population and increasing prevalence of cancer have increased the burden on healthcare systems in key countries such as the US, Japan and China. Tissue diagnostics is an important diagnostic technique for diseases such as cancer. The increasing focus on personalized medicine is gradually increasing the use of tissue diagnostics to understand disease prognosis.

In his latest publication on tissue diagnostics Meticulous Research^® states that the global Tissue Diagnostics Market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022-2029.

The global tissue diagnostics market is segmented by product type (consumables [Antibodies, Kits, Reagents]instruments [Slide Staining Systems, Slide Scanners, Tissue Processing Systems, Other Instruments {Microarray, Embedding System]), technology (immunohistochemistry, in situ hybridization, digital pathology, H&E staining of slides, other technologies), application (breast cancer, lung cancer, colon and gastrointestinal cancer, prostate cancer, lymphatic cancer, other applications), end users (hospitals and reference laboratories, research institutes, pharmaceutical companies and CROs) The study also evaluates industry competitors and analyzes their market shares at global and regional levels.

Based on geography, In 2022, North America is expected to take the largest share of this market. The growth of this regional market is attributed to the high incidence of cancer, the existence of multiple cancer awareness and diagnostic programs and the availability of advanced cancer diagnostic and treatment options.

Based on the product typeIn 2022, the Consumables segment is expected to…